Prestige Consumer Healthcare (NYSE:PBH) Upgraded to “Sell” by ValuEngine

Prestige Consumer Healthcare (NYSE:PBH) Upgraded to “Sell” by ValuEngine

August 10, 2019 Off By administrator

ValuEngine upgraded shares of Prestige Consumer Healthcare (NYSE:PBH) from a strong sell rating to a sell rating in a research report sent to investors on Friday, July 26th, ValuEngine reports.

Other equities research analysts also recently issued research reports about the stock. CIBC reiterated a hold rating and set a $84.00 target price on shares of Prestige Consumer Healthcare in a research note on Monday, May 27th. Zacks Investment Research upgraded shares of Prestige Consumer Healthcare from a sell rating to a hold rating and set a $31.00 price objective for the company in a research report on Tuesday, May 28th. Finally, TheStreet upgraded shares of Prestige Consumer Healthcare from a d+ rating to a c- rating in a research report on Tuesday, July 23rd. One analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company’s stock. The company has an average rating of Hold and an average target price of $61.07.

Shares of PBH stock traded up $0.59 during mid-day trading on Friday, hitting $33.97. 372,665 shares of the stock were exchanged, compared to its average volume of 495,943. The firm’s fifty day moving average price is $32.17. The company has a market capitalization of $1.67 billion, a PE ratio of 12.22, a price-to-earnings-growth ratio of 1.78 and a beta of 0.91. Prestige Consumer Healthcare has a 12-month low of $26.25 and a 12-month high of $41.76. The company has a quick ratio of 1.26, a current ratio of 2.16 and a debt-to-equity ratio of 1.63.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, August 1st. The company reported $0.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.01. Prestige Consumer Healthcare had a positive return on equity of 12.45% and a negative net margin of 3.81%. The company had revenue of $232.15 million for the quarter, compared to analyst estimates of $231.52 million. During the same quarter last year, the company posted $0.68 earnings per share. The business’s quarterly revenue was down 8.6% compared to the same quarter last year. As a group, analysts anticipate that Prestige Consumer Healthcare will post 2.82 earnings per share for the current year.

Institutional investors have recently modified their holdings of the business. Quadrant Capital Group LLC increased its holdings in Prestige Consumer Healthcare by 2,979.3% in the first quarter. Quadrant Capital Group LLC now owns 1,786 shares of the company’s stock valued at $53,000 after buying an additional 1,728 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Prestige Consumer Healthcare by 6.5% during the 4th quarter. Geode Capital Management LLC now owns 566,529 shares of the company’s stock worth $17,493,000 after purchasing an additional 34,514 shares in the last quarter. Eagle Asset Management Inc….

(Excerpt) To read the full article , click here
Image credit: source